The bioavailability of medetomidine in eight sheep following oesophageal administration

• 15 μg kg− 1 of Medetomidine was administered into the oesophagus of eight sheep.
• Bioavailability could not be demonstrated following this route of administration.
• Ruminal contents (microbes and ingesta) and/or the first pass effect may have contributed to this.
• Future research should consider alternative α2-agonists for this route of administration.
• Higher doses of medetomidine, administered cautiously, could also be considered.

There is sound evidence that medetomidine is an effective analgesic for acute pain in sheep. In this study, 15 μg kg− 1 of medetomidine was administered intravenously, and into the oesophagus, in a cross-over study, using eight sheep. Following intravenous administration, medetomidine could be detected in the plasma of these sheep for 120–180 min but following oesophageal administration, medetomidine could not be detected in the plasma of any sheep at any of 17 time points over four days. It is suspected that this is due to high first pass metabolism in the liver. Consequently, we conclude that future studies investigating the use of analgesics in orally-administered osmotic pumps in sheep should consider higher doses of medetomidine (e.g. > 100 μg kg− 1), further investigations into the barriers of medetomidine bioavailability from the sheep gut, liver-bypass drug delivery systems, or other α2-adrenergic agonists (e.g. clonidine or xylazine).